Results 151 to 160 of about 2,222,944 (354)
Finding novel vulnerabilities of hypomorphic BRCA1 alleles
Molecular Oncology, EarlyView.Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder +10 more
wiley +1 more source
Edge Blending to Enhance the Flow Over Double delta wing configuration during re-entry [PDF]
, 2022 Krishna Jaiswal +2 more
openalex +1 more source
, 1960 These biennial reports are summaries of the activities of this agency. They were extracted from a series of Kansas agency reports covering over 100 state agencies and institutions bound together for each biennium., 1959/1960 - 1979/1980.
Kansas. Port of Entry Board.
core
MITF maintains genome stability in nonmelanocyte lineages
Molecular Oncology, EarlyView.MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir +13 more
wiley +1 more source
Heat Transfer of Vertical Double Pipes in Velocity Entry Length
, 1960 Katsuhisa Murakawa
openalex +2 more sources
Managerial incentives and social efficiency of entry [PDF]
This paper studies the role of separation of ownership and management in determining the welfare implications of entry in oligopolistic markets. We show, in the presence of managerial incentive schemes with cost asymmetry, that entry is socially ...
Yingyi Tsai, Arijit Mukherjee
core
Molecular Oncology, EarlyView.The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source